

Holista CollTech (ASX:HCT) discovers Path-Away is 99.99pc effective against feline coronavirus

ASX:HCT MCAP \$46.80M



Ashleigh Melanko
 Markets Reporter
 ashleigh.melanko@themarketherald.com.au
 20 April 2020 13:03



CEO, Rajen Manickavasagar
 Sourced: The Edge TV

- Holista CollTech's (HCT) Path-Away ingredient has proven to be more than 99.99 per cent effective against the feline coronavirus
- Path-Away is a plant-based ingredient that is found in Holista's NatShield hand sanitiser
- It works by crippling a virus' cell walls, causing bacteria to group together and destroy themselves within seconds
- Holista has confirmed that 99.99 per cent of the coronavirus was killed within a minute of being exposed to NatShield
- Path-Away will now be subject to further testing to assess its efficacy against COVID-19 via a more direct method such as immunisation
- Results from this are expected to be released as soon as testing is completed
- Based off this news, Holista is up a steady 14.7 per cent and shares are trading for 19.5 cents each

Holista CollTech's (HCT) Path-Away ingredient has proven to be more than 99.99 per cent effective against the feline coronavirus.

The feline coronavirus is a substitute of the COVID-19 coronavirus found in humans.

What is Path-Away?

Path-Away is an active plant-based ingredient used in Holista's NatShield alcohol-free hand sanitiser and it works by crippling a virus' cell walls, causing bacteria to group together and destroy themselves within seconds.

Testing began in [mid-March](#) at microbiology laboratory in the United Kingdom to determine the efficacy of the ingredient against COVID-19.

Ingredients in Path-Away are Generally Regarded As Safe (GRAS) certified, approved by the Food and Drug Administration (FDA), and are exempt by the Environmental Protection Agency (EPA) under FIRFA 25(b) (Federal Insecticide, Fungicide and Rodenticide Act) as it is of minimal risk to humans and pets.

Path-Away has also been approved by the American Food and Safety Authority, and the Environmental Protection Authority of New Zealand.

It is developed in South Carolina by Global Infections Control Consultants LLC (GICC LLC).

As Path-Away has already proven effective against a range of viruses, fungi and bacteria, Holista and GICC LLC decided to test it against a substitute of COVID-19.

Results

Holista has confirmed that 99.99 per cent of the coronavirus was killed within a minute of being exposed to NatShield at a concentration of three per cent.

"Path-Away was subjected to high international standards of testing against COVID-19 and we are elated by the results," GICC LLC President Dr Arthur V. Martin commented.

"We hope these results will advance the global efforts to combat the spread of this coronavirus, future contagions and even the common flu by something very natural and environmentally friendly," he added.

Holista is currently in the process of registering NatShield in Australia with the Therapeutic Goods Administration (TGA) and will apply for a permit claiming that it is effective against COVID-19 as per the TGA's guidelines.

However, if this permit is not granted then it will not grant NatShield as effective against COVID-19.

"This is highly significant for NatShield. The results have satisfied the European standard that applies to areas and situations where disinfection is medically indicated," Holista CEO Dr Rajen Manicka stated.

"This scientific validation means that NatShield can be used to sanitise the hands without the need for rinsing, can be applied to the face and even inside the nose without irritation and is not harmful even if swallowed," he continued.

"It may also be sprayed safely to sanitise a person's immediate surrounding space, without any negative effects," he said.

What's next?

Path-Away will now be subject to further testing to assess its efficacy against COVID-19 via a more direct method such as immunisation.

This testing is being completed at Biosafety Laboratory approved by the Centres for Disease Control in the United States.

Results from this are expected to be released as soon as testing is completed.

Based off this news, Holista is up a steady 14.7 per cent and shares are trading for 19.5 cents each at 12:10 pm AEST.